PATH holds $1.5B cash, trades at ~4x last year’s revenue, and just posted its first positive EPS; 30% of float is short. The combination of undervaluation, accelerating enterprise AI adoption, and high short interest creates a squeeze/rerating opportunity. Buy calls (Jan ’27 $15c) to play medium-term growth and potential gamma/squeeze on earnings. Earnings miss, competition from other automation/AI integration platforms, macro-driven tech selloff, or failure to convert growth into sustained profitability.
PATH holds $1.5B cash, trades at ~4x last year’s revenue, and just posted its first positive EPS; 30% of float is short. The combination of undervaluation, accelerating enterprise AI adoption, and high short interest creates a squeeze/rerating opportunity. Buy calls (Jan ’27 $15c) to play medium-term growth and potential gamma/squeeze on earnings. Earnings miss, competition from other automation/AI integration platforms, macro-driven tech selloff, or failure to convert growth into sustained profitability.